Stock VERV VERVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Real-time Estimate Cboe BZX
Other stock markets
 15:30:53 2024-04-29 EDT 		5-day change 1st Jan Change
6.15 USD -0.16% Intraday chart for Verve Therapeutics, Inc. -11.29% -56.03%
04-03 Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating MT
04-02 Sector Update: Health Care Stocks Slide Late Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
PR
Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Top Midday Decliners
MT
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
MT
Sector Update: Health Care
MT
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell
MT
Top Premarket Decliners
MT
Verve Therapeutics Announces Updates on its PCSK9 Program
GL
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
RE
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program
CI
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise
MT
Verve Therapeutics: Q4 Earnings Snapshot
AQ
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERV Stock
  4. News Verve Therapeutics, Inc.